Browse News
Filter News
Found 808,534 articles
-
The first Bioversity cohort includes several graduates placed at Massachusetts life sciences companies.
-
How to Deal With Layoff-Related Stress
4/18/2024
Employees worried about layoffs can practice self-care, use employer resources and contact a mental health professional, if needed. -
Plus, what to expect in a phone screen and how to handle an impending layoff.
-
Intra-Cellular Therapies Prices Public Offering of Common Stock - April 18, 2024
4/18/2024
Intra-Cellular Therapies, Inc. announced the pricing of its previously announced underwritten public offering of 6,849,316 shares of its common stock at a public offering price of $73.00 per share.
-
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
4/18/2024
Chemomab Therapeutics Ltd. today announced the publication of a new study that further confirms the key role of its novel soluble protein target CCL24 in systemic sclerosis (SSc).
-
Redwood Scientific Technologies Inc.today announced a strategic shift in its product development priorities
4/18/2024
Redwood Scientific Technologies Inc. (OTC: RSCI) ("Redwood" or "the Company"), a pharmaceutical company, today announced a strategic shift in its product development priorities.
-
Cantargia Publishes Annual Report for 2023
4/18/2024
Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today announced that the annual report for 2023 has been published.
-
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
4/18/2024
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado.
-
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
4/18/2024
Benitec Biopharma Inc. today announces positive interim clinical data from the 90-day timepoint following the administration of BB-301 to the study’s first subject (Subject 1) treated in the BB-301 Phase 1b/2a single-arm, open-label, sequential, dose-escalation cohort study (NCT06185673) in Oculopharyngeal Muscular Dystrophy (OPMD).
-
EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS
4/18/2024
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Variant Bio, Inc. today announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis.
-
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
4/18/2024
Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported its full-year 2023 financial results for the period ended December 31, 2023 and provided a corporate update.
-
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
4/18/2024
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry.
-
TaiGen Successfully Completes TG-1000 Phase III Study
4/18/2024
TaiGen Biotechnology Company, Limited announces that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study.
-
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
4/18/2024
Revive Therapeutics Ltd. announced today that the U.S. Food & Drug Administration (“FDA”) has accepted the Company’s meeting request for the Revive LC POC Lateral Flow Test Kit.
-
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
4/18/2024
Bio-Path Holdings, Inc. today announced completion of the second dose cohort of the dose escalation portion of its Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia.
-
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
4/18/2024
Benitec Biopharma Inc. today announced a $40.0 million private investment in public equity (PIPE) financing from the sale of 5,749,152 shares of its common stock at a price per share.
-
Morphoceuticals Names Jim Jenson, PhD as CEO to Advance AI-Guided Regenerative Medicine Technology
4/18/2024
Morphoceuticals Inc. announced the appointment of veteran biotech executive Jim Jenson, PhD, as CEO. Jenson joins a growing team and will lead the company as it advances its novel regenerative medicine technology platform.
-
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
4/18/2024
Cerevel Therapeutics announced positive topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon, the first and only D1/D5 receptor partial agonist being studied as a once-daily treatment for Parkinson’s disease.
-
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
4/18/2024
TG Therapeutics, Inc. (NASDAQ: TGTX), announced that it has been awarded a national contract with the Department of Veterans Affairs (VA) for BRIUMVI® (ublituximab-xiiy) to be the preferred agent listed on the VA National Formulary for Anti-CD20 Antibody indications for patients with relapsing forms of multiple sclerosis (RMS).
-
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
4/18/2024
Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced additional data analyses from the 2-year Phase 3 NeflgArd trial evaluating Nefecon (TARPEYO® (budesonide) delayed-release capsules/Kinpeygo®) in patients with IgA nephropathy (IgAN), were presented at the ISN World Congress of Nephrology in Buenos Aires, Argentina on April 13-16, 2024.